Angelman Syndrome Market

The total prevalent cases of Angelman Syndrome in the seven major markets was 57,716 in 2017. Among the 7MM, the prevalence of Angelman Syndrome in the United States and Germany were found to be 21,715 and 6,448 respectively in 2017.

The therapeutic market of Angelman Syndrome in the 7MM was USD 255 Million in 2017, which is expected to increase during the forecast period 2017-2030.

The key players in the Angelman Syndrome market include Ovid Therapeutics, GeneTx Biotherapeutics, PTC Therapeutics and many others.

For more details on Angelman Syndrome Market visit: https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast